Disomotide

N/A

Report date: 2023/01/19 20:00:22
NME

Base Information

Drug NameDisomotide
Drug Alias Namedisomotide地索莫泰地索莫肽disomotidadisomotidum +[11] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsUveal melanomaSkin MelanomaNeoplasm Metastasis +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBristol Myers Squibb SrlcompanyNational Cancer InstituteThe University Of Texas MD Anderson Cancer Center +[4] 
Active IndicationsN/A
Inactive IndicationsUveal melanomaSkin MelanomaNeoplasm Metastasis +[6] 

Other Information

ATC CodeN/A
Related LinksN/A